KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Emergent BioSolutions (EBS) over the last 12 years, with Dec 2024 value amounting to $27.2 million.

  • Emergent BioSolutions' Asset Writedowns and Impairment was N/A to $12.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $14.1 million, marking a year-over-year change of. This contributed to the annual value of $27.2 million for FY2024, which is 91.13% down from last year.
  • Emergent BioSolutions' Asset Writedowns and Impairment amounted to $27.2 million in FY2024, which was down 91.13% from $306.7 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Asset Writedowns and Impairment high stood at $306.7 million for FY2023, and its period low was $27.2 million during FY2024.
  • Over the past 2 years, Emergent BioSolutions' median Asset Writedowns and Impairment value was $166.9 million (recorded in 2023), while the average stood at $166.9 million.
  • In the last 5 years, Emergent BioSolutions' Asset Writedowns and Impairment spiked by 141.67% in 2020 and then crashed by 91.13% in 2024.
  • Emergent BioSolutions' Asset Writedowns and Impairment (Yearly) stood at $29.0 million in 2020, then reached $306.7 million in 2023, then plummeted by 91.13% to $27.2 million in 2024.